C2N Diagnostics, LLC ("C2N"), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, is ...
CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ('Plus” or the 'Company”), announced today that it has signed a national agreement with UnitedHealthcare ...
Explore how machine learning is revolutionising interstitial lung disease management, enhancing early diagnosis, treatment, ...
Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 11:20 AM EDTCompany ParticipantsPriya Singhal - Executive ...
The gene therapy company uniQure has announced top-level data from its trial of AMT-130, a new gene therapy designed to treat ...
Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity score-matched external cont ...
Kerala is facing a rise in brain-eating amoeba infections, but increased detection efforts, including CSF analysis, explain ...
The 2024 McDonald criteria, published just before the 2025 ECTRIMS Congress, substantially expand criteria for a probable diagnosis of multiple sclerosis, experts report.
Discover Alector's latest breakthroughs in neurodegenerative disease therapies, including updates on Alzheimer's and Parkinson's programs.
Key points New evidence has led to a change in the way that some patients with amyotrophic lateral sclerosis (ALS) are classified and treated. Based on the findings of a landmark trial,[1][1] the drug ...
Li, Y. and Liu, J. (2025) An Accessible Predictive Model for Alzheimer’s Disease Based on Cognitive and Neuropathological ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback